WB, IP
H M R Mk
Endogenous
37
Rabbit
#Q9NQG5
58490
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human RPRD1B protein. Antibodies are purified by peptide affinity chromatography.
Background
Regulation of nuclear pre-mRNA domain-containing 1B (RPRD1B), also known as cell cycle-related and expression-elevated protein in tumor (CREPT), is a transcriptional regulator that interacts with the POLR2A catalytic subunit of RNA polymerase II (Pol II) (1). It is also an oncoprotein that promotes cell proliferation and is upregulated in a variety of cancers, including gastric, colorectal, and non-small cell lung cancer (NSCLC) (2-4). RPRD1B contains a CTD-interacting domain (CID), which interacts with the C-terminal domain (CTD) of Pol II to regulate transcription termination (5). It is believed that this association enhances the binding of Pol II to the CCND1 promoter, thereby increasing cyclin D1 transcription and promoting tumorigenesis (6). Specifically, RPRD1B promotes chromatin looping of the CCND1 gene to recycle Pol II from the termination site to the promoter region (6). RPRD1B may also regulate the transcription of various genes through associations with STAT3 and the histone acetyltransferase p300 (7,8).
- Ni, Z. et al. Transcription 2, 237-42.
- Ding, L. et al. (2018) Cell Death Dis 9, 1172.
- Zhang, Y. et al. (2018) Oncogene 37, 3485-3500.
- Jung, H.M. et al. (2009) J Cell Biochem 106, 703-13.
- Ali, I. et al. (2019) Mol Cell 74, 1164-1174.e4.
- Lu, D. et al. (2012) Cancer Cell 21, 92-104.
- Zhang, Y. et al. (2014) J Biol Chem 289, 22589-22599.
- Zhai, W. et al. (2021) Br J Cancer 124, 1437-1448.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
